Get the Stockscreener App
4.55
4.01%
-0.19
After Hours:
4.50
-0.05
-1.10%
Cingulate Inc stock is traded at $4.55, with a volume of 287.14K.
It is down -4.01% in the last 24 hours and down -8.63% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.74
Open:
$4.9
24h Volume:
287.14K
Relative Volume:
1.74
Market Cap:
$14.39M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1396
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
-10.78%
1M Performance:
-8.63%
6M Performance:
+13.35%
1Y Performance:
-87.19%
1-Day Range:
$4.37
$4.90
1-Week Range:
$4.37
$5.15
52-Week Range:
$1.8001
$58.32
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.55 | 14.39M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate stock price target raised to $20 at H.C. Wainwright By Investing.com - Investing.com South Africa
Cingulate stock price target raised to $20 at H.C. Wainwright - Investing.com India
Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Public company CEO concludes case alleging aggravated domestic battery - The Business Journals
Cingulate Inc. adjusts executive compensation - Investing.com India
Cingulate Inc. adjusts executive compensation By Investing.com - Investing.com UK
Jane Street Group LLC Invests $106,000 in Cingulate Inc. (NASDAQ:CING) - Defense World
Cingulate stock rated Buy by Roth/MKM, anticipates $1.6B sales potential - Investing.com Canada
Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm - Defense World
Roth Capital Upgrades Cingulate (NASDAQ:CING) to “Strong-Buy” - Defense World
Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation - MSN
CINGWCingulate Inc. Warrants Latest Stock News & Market Updates - StockTitan
Cingulate Inc Completes Key FDA Study for ADHD Drug - TipRanks
Final Study Completed for Cingulate’s Lead Asset CTx-1301 - GlobeNewswire
Cingulate Completes Final FDA Study for Once-Daily ADHD Drug CTx-1301 with Zero Safety Issues - StockTitan
Cingulate Inc. Enters into Note Purchase Agreement with Streeterville Capital, LLC - Defense World
Cingulate secures capital ahead of 2025 plans to submit drug for FDA approval - The Business Journals
Cingulate Inc Secures $5M Financing for Strategic Growth - Yahoo Finance
Cingulate Inc. announced that it has received $5 million in funding - Marketscreener.com
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - GlobeNewswire
Cingulate Secures $5M Financing Deal to Advance CTx-1301 Drug Development Through 2025 - StockTitan
Cingulate (NASDAQ:CING) Upgraded at Maxim Group - Defense World
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Cingulate Inc. Announces Third Quarter Financial Results and Clinical Update - Defense World
Cingulate Inc (CING) Quarterly 10-Q Report - Quartz
CINGCingulate Inc. Latest Stock News & Market Updates - StockTitan
Cingulate reports Q3 net loss $3.2M vs. $5.98M last year - TipRanks
Cingulate Reports Third Quarter 2024 Financial - GlobeNewswire
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - StockTitan
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - The Manila Times
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewswire
Cingulate secures funding to extend operations into Q2 2025 By Investing.com - Investing.com South Africa
SEC Form 424B3 filed by Cingulate Inc. - Quantisnow
Cingulate secures funding to extend operations into Q2 2025 - Investing.com India
Cingulate Inc Files for 1.5M Share Offering by Selling Stockholders - Investing.com Canada
Cingulate Inc. CEO faces domestic battery charge - Investing.com India
Cingulate Inc. CEO faces domestic battery charge By Investing.com - Investing.com South Africa
KC-area public company CEO faces charges for aggravated domestic battery - The Business Journals
Cingulate files to sell 1.5M shares of common stock for holders - MSN
Will Ciena's New 1.6 Tb/s Coherent Pluggable Solution Drive Top Line? - Zacks Investment Research
Concentrix Corp (CNXC) Q3 2024: Everything You Need to Know Ahea - GuruFocus.com
Cettire shares skyrocket - Finance News Network
Cettire gets auditor’s tick of approval, adding $247m to valuation - The Australian Financial Review
Stock of the day: Cettire - IG
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Why Ciena Stock Popped 5% on Monday - The Motley Fool
Double-Upgrade Pushes Ciena Stock Near Record Highs - Schaeffers Research
Citi upgrades Ciena, shares rise in pre-market trade By Investing.com - Investing.com Canada
9 Analysts Assess Ciena: What You Need To Know - Benzinga
Ciena Unveils 1.6 Tb/s Coherent Pluggable Solution for Hyperscale Cloud Providers' Capacity Surge - Marketscreener.com
Ciena's stock rises after Citi double upgrades to Buy (NYSE:CIEN) - Seeking Alpha
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):